Your browser is no longer supported. Please, upgrade your browser.
ONCT Oncternal Therapeutics, Inc. daily Stock Chart
Oncternal Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.27 Insider Own5.90% Shs Outstand16.24M Perf Week-1.36%
Market Cap53.25M Forward P/E- EPS next Y- Insider Trans102.00% Shs Float9.85M Perf Month25.43%
Income-36.60M PEG- EPS next Q- Inst Own16.50% Short Float0.35% Perf Quarter13.67%
Sales2.50M P/S21.30 EPS this Y-101.10% Inst Trans94.74% Short Ratio0.47 Perf Half Y-26.33%
Book/sh0.59 P/B4.93 EPS next Y- ROA- Target Price- Perf Year-35.33%
Cash/sh- P/C- EPS next 5Y0.00% ROE- 52W Range2.11 - 6.29 Perf YTD-26.33%
Dividend- P/FCF- EPS past 5Y37.10% ROI-231.50% 52W High-53.74% Beta1.17
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low37.61% ATR0.24
Employees11 Current Ratio2.00 Sales Q/Q-14.30% Oper. Margin- RSI (14)53.61 Volatility7.37% 8.42%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.39 Prev Close2.99
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume73.78K Price2.91
Recom3.00 SMA205.17% SMA503.71% SMA200-20.04% Volume28,493 Change-2.68%
Aug-06-20 04:15PM  
Jul-30-20 08:00AM  
Jul-27-20 08:00AM  
Jul-20-20 08:00AM  
Jun-30-20 08:00AM  
May-20-20 08:00AM  
May-19-20 08:00AM  
May-07-20 08:00AM  
May-05-20 08:00AM  
May-01-20 08:00AM  
Mar-18-20 08:36AM  
Mar-16-20 04:05PM  
Mar-11-20 04:08PM  
Feb-06-20 08:00AM  
Dec-12-19 06:00PM  
Dec-11-19 08:00AM  
Dec-09-19 08:00AM  
Dec-03-19 08:00AM  
Nov-21-19 08:00AM  
Nov-14-19 04:02PM  
Nov-11-19 08:00AM  
Nov-07-19 04:05PM  
Nov-05-19 08:00AM  
Oct-31-19 08:00AM  
Oct-03-19 08:00AM  
Sep-20-19 12:03PM  
Sep-17-19 04:05PM  
Sep-09-19 08:00AM  
Aug-28-19 04:01PM  
Aug-08-19 04:01PM  
Aug-06-19 08:00AM  
Aug-01-19 04:01PM  
Jun-10-19 08:00AM  
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AKER HAZEL MLegal CounselJul 21Buy2.3841,97299,99846,987Jul 23 05:00 PM
KISNER DANIEL LDirectorJul 21Buy2.3810,00023,82510,000Jul 23 05:00 PM
Shanghai Pharmaceutical (USA) 10% OwnerJul 21Buy2.381,049,3172,499,9983,544,431Jul 23 04:32 PM